Mg, Ca and Ba glutaratouranylates – Synthesis and structure

The CD38 glycohydrolase and the NAD sink: implications for pathological conditions

Nicotinamide adenine dinucleotide (NAD) acts as a cofactor in several oxidation-reduction (redox) reactions and is a substrate for a number of nonredox enzymes. NAD is fundamental to a variety of cellular processes including energy metabolism, cell signaling, and epigenetics. NAD homeostasis appears to be of paramount importance to health span and longevity, and its dysregulation is associated with multiple diseases. NAD metabolism is dynamic and maintained by synthesis and degradation. The enzyme CD38, one of the main NAD-consuming enzymes, is a key component of NAD homeostasis. The majority of CD38 is localized in the plasma membrane with its catalytic domain facing the extracellular environment, likely for the purpose of controlling systemic levels of NAD. Several cell types express CD38, but its expression predominates on endothelial cells and immune cells capable of infiltrating organs and tissues. Here we review potential roles of CD38 in health and disease and postulate ways in which CD38 dysregulation causes changes in NAD homeostasis and contributes to the pathophysiology of multiple conditions. Indeed, in animal models the development of infectious diseases, autoimmune disorders, fibrosis, metabolic diseases, and age-associated diseases including cancer, heart disease, and neurodegeneration are associated with altered CD38 enzymatic activity. Many of these conditions are modified in CD38-deficient mice or by blocking CD38 NADase activity. In diseases in which CD38 appears to play a role, CD38-dependent NAD decline is often a common denominator of pathophysiology. Thus, understanding dysregulation of NAD homeostasis by CD38 may open new avenues for the treatment of human diseases.

Structure-Directing Effects of Counterions in Uranyl Ion Complexes with Long-Chain Aliphatic α,ω-Dicarboxylates: 1D to Polycatenated 3D Species

Nine uranyl ion complexes were synthesized under (solvo-)hydrothermal conditions using α,ω-dicarboxylic acids HOOC-(CH₂) _n-2-COOH (H₂C n, n = 6-9) and diverse counterions. Complexes [PPh₄][UO₂(C6)(NO₃)] (1) and [PPh₄][UO₂(C8)(NO₃)] (2) contain zigzag one-dimensional (1D) chains, with further polymerization being prevented by the terminal nitrate ligands. [PPh₃Me][UO₂(C7)(HC7)] (3) crystallizes as a 1D polymer with a curved section, with hydrogen bonding of the uncomplexed carboxylic groups giving rise to formation of 3-fold interpenetrated two-dimensional (2D) networks. [PPh₄][H₂NMe₂][(UO₂)₂(C7)₃] (4) and [PPh₃Me]₂[(UO₂)₂(C8)₃] (5) contain 1D chains, either ladder-like or containing doubly bridged dimers, while [PPh₃Me]₂[(UO₂)₂(C9)₃]·2H₂O (6) displays interdigitated, strongly corrugated honeycomb 2D nets. Ladder-like 1D polymers in [Cu( R,S-Me₆cyclam)][(UO₂)₂(C7)₂(C₂O₄)]·4H₂O (7) are associated into layers by the hydrogen bonded counterions, whereas the [Ni(cyclam)]²⁺ moieties are part of the 2D polymeric arrangement in [(UO₂)₂(C7)₂(HC7)₂Ni(cyclam)]·2H₂O (8) because of axial coordination of the nickel(II) center, with hydrogen bonding mediated by water molecules generating a three-dimensional (3D) net. [(UO₂)₂K₂(C7)₃(H₂O)]·0.5H₂O (9) contains convoluted uranyl dicarboxylate 2D subunits, which generate a 3D framework through 2D → 3D parallel polycatenation similar to that previously found in [NH₄]₂[(UO₂)₂(C7)₃]·2H₂O; further linking of these subunits is provided by bonding of the potassium cations to carboxylate and uranyl oxido groups. The solid-state emission spectra of complexes 1-6 and 9 display maxima positions typical of hexacoordinated uranyl carboxylate complexes, but uranyl luminescence is quenched in 7. A solid-state photoluminescence quantum yield of 11.5% has been measured for complex 1, while those for compounds 3-6 and 9 are in the range of 2.0-3.5%.